Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome : study protocol for a randomized controlled trial

Show full item record



Permalink

http://hdl.handle.net/10138/229015

Citation

Bellingan , G , Brealey , D , Mancebo , J , Mercat , A , Patroniti , N , Pettilä , V , Quintel , M , Vincent , J-L , Maksimow , M , Jalkanen , M , Piippo , I & Ranieri , V M 2017 , ' Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome : study protocol for a randomized controlled trial ' , Trials , vol. 18 , 536 . https://doi.org/10.1186/s13063-017-2234-7

Title: Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome : study protocol for a randomized controlled trial
Author: Bellingan, Geoff; Brealey, David; Mancebo, Jordi; Mercat, Alain; Patroniti, Nicolo; Pettilä, Ville; Quintel, Michael; Vincent, Jean-Louis; Maksimow, Mikael; Jalkanen, Markku; Piippo, Ilse; Ranieri, V. Marco
Contributor organization: Clinicum
Department of Diagnostics and Therapeutics
HUS Perioperative, Intensive Care and Pain Medicine
Date: 2017-11-13
Language: eng
Number of pages: 9
Belongs to series: Trials
ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-017-2234-7
URI: http://hdl.handle.net/10138/229015
Abstract: Background: Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN) beta-1a up-regulates the cell surface ecto-5'-nucleotidase cluster of differentiation 73 (CD73), which increases adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS. In a phase I/II, open-label study in 37 patients with acute lung injury (ALI)/ARDS, recombinant human IFN beta-1a was well tolerated and mortality rates were significantly lower in treated than in control patients. Methods/design: In this phase III, double-blind, randomized, parallel-group trial, the efficacy and safety of recombinant human IFN beta-1a (FP-1201-lyo) will be compared with placebo in adult patients with ARDS. Patients will be randomly assigned to receive 10 mu g FP-1201-lyo or placebo administered intravenously once daily for 6 days and will be monitored for 28 days or until discharged from the intensive care unit. Follow-up visits will then take place at days 90, 180 and 360. The primary endpoint is a composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors. Secondary endpoints include: all-cause mortality at 28, 90, 180 and 360 days; organ failure-free days; length of hospital stay; pharmacodynamic assessment including measurement of myxovirus resistance protein A concentrations; and measures of quality of life, respiratory and neurological function at 180 and 360 days. The estimated sample size to demonstrate a reduction in the primary outcome between groups from 30% to 15% is 300 patients, and the study will be conducted in 70-80 centers in nine countries across Europe. Discussion: There are no effective specific treatments for patients with ARDS and mortality rates remain high. The results from this study will provide evidence regarding the efficacy of a potential new therapeutic agent, FP-1201-lyo, in improving the clinical course and outcome for patients with moderate/severe ARDS.
Subject: Interferon
ARDS
Vascular leakage
CD73
ACUTE LUNG INJURY
VASCULAR LEAKAGE
MORTALITY
OUTCOMES
MECHANISMS
COSTS
CARE
3111 Biomedicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
s13063_017_2234_7.pdf 536.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record